

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
08 June 2023 (08.06.2023)



(10) International Publication Number  
**WO 2023/102225 A2**

(51) International Patent Classification:  
C12N 15/85 (2006.01) A61K 31/712 (2006.01)

(21) International Application Number:  
PCT/US2022/051713

(22) International Filing Date:  
02 December 2022 (02.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/285,786 03 December 2021 (03.12.2021) US  
63/350,206 08 June 2022 (08.06.2022) US  
63/398,987 18 August 2022 (18.08.2022) US

(71) Applicant: **QURALIS CORPORATION** [US/US]; 100  
Cambridgepark Drive, Suite 500, Cambridge, Massachu-  
setts 02140 (US).

(72) Inventors; and

(71) Applicants: **HINCKLEY, Sandra** [US/US]; c/o Quralis  
Corporation, 100 Cambridgepark Drive, Suite 500, Cam-  
bridge, Massachusetts 02140 (US). **BROWN, Duncan**  
[US/US]; c/o Quralis Corporation, 100 Cambridgepark Drive,  
Suite 500, Cambridge, Massachusetts 02140 (US). **EL-  
BAUM, Daniel** [US/US]; c/o Quralis Corporation, 100  
Cambridgepark Drive, Suite 500, Cambridge, Massachu-  
setts 02140 (US).

(72) Inventor: **KAMELGARN, Marisa Elizabeth**; c/o Quralis  
Corporation, 100 Cambridgepark Drive, Suite 500, Cam-  
bridge, Massachusetts 02140 (US).

(74) Agent: **ZHANG, Clark et al.**; Goodwin Procter LLP, 100  
Northern Avenue/IP Docketing 7th fl, Boston, Massachu-  
setts 02210 (US).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,  
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,  
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,  
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,  
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,  
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— of inventorship (Rule 4.17(iv))

**Published:**

— without international search report and to be republished  
upon receipt of that report (Rule 48.2(g))

(54) Title: TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF UNC13A GENE TRANSCRIPTS




FIGURE 1

(57) Abstract: Disclosed herein are UNC13A oligonucleotides with one or more spacers or without a spacer. In various embodiments, UNC13A oligonucleotides with spacer(s) reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).

WO 2023/102225 A2